Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Febuxostat versus allopurinol in Chinese adults with asymptomatic hyperuricemia and chronic kidney disease
ChiCTR-IPR-17011837Phase 4Recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of febuxostat and allopurinol in hyperuricemia and chronic kidney disease (CKD) (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Serum uric acid. Started Jul 2017; status: recruiting.
02
Drugs
febuxostatallopurinol
03
Conditions
hyperuricemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR-IPR-17011837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011837.